Funding for this research was provided by:
The European Society for Sexual Medicine
Received: 2 May 2022
Accepted: 6 January 2023
First Online: 3 February 2023
: All participants signed informed consent. The study was registered and approved by the Capital Region’s Knowledge Center for Data Reviews.
: All authors and participants consent to the publication of the manuscript.
: MV has received a consultancy fee from Lundbeck, Janssen-Cilag and Sunovion. AMG has been a speaker for Pfizer, Astellas, Viatris, and Eli Lilly, on the advisory board for Futura Medical and OvacoBio, consultant for Eli Lilly, and stockholder in Novo Nordic. The remaining authors have no competing interests to declare.